Dernières nouvelles pour Pfizer (NYSE:PFE) Stock

Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Pfizer Inc

Innovator U.S. Equity Power Buffer ETF - February

PFEIFFER VACUUM TECH ORD by Pfeiffer Vacuum Technology AG

Pfeiffer Vacuum Technology AG

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">respiratory tract disease (LRTD)</a>.
In June 2024, ACIP postponed a vote on a recommendation for adults aged 50-59 at increased risk for RSV-LRTD until additional <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39522040/cdc-advisor-panel-recommends-rsv-shots-in-us-for-people-above-75-years-analyst-says-decision-nega" rel="noreferrer noopener">data becomes available</a>.
The update includes Pfizer Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Abrysvo (Respiratory Syncytial Virus Vaccine), which the U.S. Food and Drug Administration approved in October 2024 for the prevention of RSV-associated LRTD in adults aged 18 to 59 at increased <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41493556/fda-approves-pfizers-respiratory-syncytial-virus-vaccine-abrysvo-for-adults-below-60-years" rel="noreferrer noopener">risk of severe disease</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction" rel="noreferrer noopener">Trump&#8217;s New Order Targets Drug Pricing Transparency And Medicare Cost Reduction</a>
The recommendation also includes GSK plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Arexvy in adults aged 50-59 who are at increased risk <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44853850/arexvy-recommended-for-adults-aged-50-59-at-increased-risk-for-severe-respiratory-syncytial-virus-" rel="noreferrer noopener">for severe RSV disease</a>.
This expands on ACIP&#8217;s previous vote in June 2024 to recommend RSV vaccines for adults aged 60-74 who are at increased risk and all adults aged 75 and older.
Arexvy is indicated for the prevention of LRTD caused by RSV in individuals 60 years of age and older and individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.
According to the CDC, between 15,000 &#8211; 20,000 RSV-associated hospitalizations occur annually in U.S. adults <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44852139/acip-votes-to-expand-recommendation-for-pfizers-rsv-vaccine-abrysvo-to-include-adults-aged-50-to-5" rel="noreferrer noopener">aged 50 &#8211; 59 years</a>.
A systematic review of studies in the U.S. shows that RSV is estimated to cause 42,000 hospitalizations each year in adults aged 50-64 years old.
GSK said the ACIP considered results from a phase 3 trial evaluating the immune response and safety of GSK&#8217;s RSV vaccine in adults aged 50-59, including those at increased risk for RSV-LRTD due to certain underlying medical conditions compared to older adults aged 60 years and older where efficacy has been demonstrated after a single dose of GSK&#8217;s RSV vaccine.
The updated recommendation does not benefit Moderna Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) mRNA-based RSV vaccine mRESVIA (mRNA-1345), which is currently approved for adults over 60 years.
William Blair notes Moderna shared Phase 3 data for mRNA-1345 in high-risk adults aged 18-59 at its 2024 R&amp;D Day event and has since submitted an application to the FDA for regulatory approval using a priority review voucher.&nbsp;The FDA <a target="_blank" href="https://investors.modernatx.com/news/news-details/2025/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2024-Financial-Results-and-Provides-Business-Updates/default.aspx" rel="noreferrer noopener">has</a> accepted Moderna&#8217;s application and has assigned a PDUFA goal date of June 12, 2025.
Analyst Myles R. Minter highlights the Phase 3 trial of mRNA-1345 in over 1,000 high-risk individuals between ages 18 and 59. mRNA-1345 demonstrated non-inferior immunogenicity compared to adults age 60 or older for neutralizing antibodies against both RSV-A and RSV-B and a tolerable safety profile.
&#8220;If approved on time, we believe mRESVIA could be added to the updated age group recommendation during the scheduled June 25-26, 2025, ACIP meeting,&#8221; Minter said.
Price Action: PFE stock is up 1.07% 22.28, MRNA stock is down 2.30% at $24.62, and GSK stock is up 1.74% at $35.98 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44860903/eli-lillys-oral-glp-1-drug-orforglipron-hits-phase-3-goals-in-diabetes-trial-stock-shoots-higher" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars</a></li>
</ul>
Photo by pedro7merino via Shutterstock

Biotech

Large Cap

News

Health Care

General

MRNA

US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years

Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Thursday reported topline Phase 3 results from ACHIEVE-1 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">diet and exercise alone</a>.
In the first Phase 3 trial of the ACHIEVE program, orforglipron met the primary endpoint of superior A1C (blood sugar) reduction compared to placebo at 40 weeks, lowering A1C by an average of 1.3% to 1.6% from a baseline of 8.0%, <a target="_blank" href="https://www.benzinga.com/25/04/44860903/eli-lillys-oral-glp-1-drug-orforglipron-hits-phase-3-goals-in-diabetes-trial-stock-shoots-higher" rel="noreferrer noopener">using the efficacy estimand</a>.
BofA Securities analyst Tim Anderson writes, &#8220;Arguably one of the biggest, most important, most closely-watched pipeline events in large cap biopharma has just played out. And it was favorable.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction" rel="noreferrer noopener">Trump&#8217;s New Order Targets Drug Pricing Transparency And Medicare Cost Reduction</a>
Anderson says the only other current oral GLP-1 drug is Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Rybelsus (semaglutide), a peptide with some limitations.
&#8220;The &#8220;key&#8221; with orforglipron is that it is a &#8220;small molecule&#8221; drug, meaning easy to scale and produce &#8211; recall past manufacturing problems with injectable GLP-1s (from Eli Lilly and Novo Nordisk),&#8221; Anderson adds.
An oral drug like this can help expand obesity treatment outside the U.S., especially in developing countries where keeping medications cold is difficult.
BofA writes Eli Lilly is mainly focusing on selling the oral version in markets outside the U.S., where prices need to be lower. Since oral drugs are easier and cheaper to produce, this makes sense.
&#8220;Positive results like these, in a skittish market, should be received well,&#8221; BofA writes.
BofA forecasts 2030 orforglipron sales of around $10 billion compared to a consensus of around $9 billion.
The analyst maintains the Buy rating, with a price forecast of $1,000.
Anderson writes, &#8220;On a macro perspective, we believe that given the strength of the Phase II data, positive Phase III ACHIEVE-1 efficacy results were expected. However, in light of Pfizer Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) recent discontinuation of danuglipron, tolerability and hepatotoxicity have emerged as more important clinical attributes, in our view.&#8221;
Price Action: LLY stock is up 16.3% at $854.84 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44866751/forge-global-eyes-strategic-expansion-with-10m-accuidity-acquisition" target="_blank" rel="noreferrer noopener">Forge Global Eyes Strategic Expansion With $10 Million Accuidity Acquisition</a></li>
</ul>
Photo by shisu_ka via Shutterstock

Analyst Color

Analyst Ratings

Movers

Trading Ideas

Lilly's Diabetes Pill Clears Major Trial, Analyst Points To Global Potential

Billionaire entrepreneur Mark Cuban has expressed support for President Donald Trump&#8216;s 2025 healthcare executive order, emphasizing its potential to reform the role of Pharmacy Benefit Managers (PBMs) in the U.S. healthcare system.
What Happened: In a post on X, addressed to President Trump on Wednesday, Cuban cheered the order that aims to reform PBMs, entities that control 80% of U.S. prescriptions. He emphasized the potential of the order to save billions and improve patient wellness.
Cuban&#8217;s proposals include separating&nbsp;formularies from PBMs to focus&nbsp;on wellness, mandating transparency in&nbsp;claims data to improve patient&nbsp;outcomes, and eliminating&nbsp;specialty drug tiers that inflate&nbsp;costs. He also urged action on issues such as the 340B program's double-dipping, which a 2023 study estimated to cost hospitals $500 million each year.
&#8220;Make them about wellness, not pay for play like a grocery store endcap. This ends rebates and allows for net pricing. It also allows for better care and wellness,&#8221; stated the Shark Tank celebrity. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Gotta be honest. The <a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a> EO on healthcare and in particular, drug pricing could save hundreds of billions. Here is how: 1. Divorce formularies from PBMs. Require them to come from independent organizations with no economic incentive from the formulary Make them…
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1912628036668739778?ref_src=twsrc%5Etfw">April 16, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cuban, the founder of Cost Plus Drug Company, also criticized&nbsp;PBM tactics like biosimilar substitution&nbsp;calls, where they push doctors&nbsp;to prescribe pricier drugs for&nbsp;higher margins, a practice enabled&nbsp;by vertical integration. He referenced the&nbsp;1990s FTC concerns when pharmaceutical&nbsp;companies acquired PBMs, leading to&nbsp;mandated open formularies.
SEE ALSO: <a href="https://benzinga.com/news/global/25/04/44856008/china-dismisses-trumps-tariff-numbers-game-files-wto-complaint-talks-can-only-proceed-based-on-mutual" target="_blank" rel="noreferrer noopener">China Dismisses Trump&#8217;s Tariff &#8216;Numbers Game,&#8217; Files WTO Complaint: Talks Can Only Proceed Based On &#8216;Mutual Respect&#8217;</a>
Why It Matters: Trump&#8217;s executive order comes as part of a <a href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction">broader effort</a> to lower drug prices and reduce Medicare costs. The administration is set to negotiate prices for a second batch of 15 medications, including Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, along with Pfizer's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) cancer treatments Ibrance and Xtandi
Additionally, the Trump administration has disclosed plans for a "major tariff" on <a href="https://www.benzinga.com/government/regulations/25/04/44847222/trump-administration-opens-probe-into-foreign-drug-imports-eyes-tariffs-under-national-security-law">foreign pharmaceuticals</a>. This move could potentially impact the pharmaceutical industry, with the U.S. Department of Commerce launching an investigation into the potential national security risks posed by the country's reliance on imported pharmaceuticals and key drug ingredients.
Meanwhile, Cuban, an outspoken critic of the Trump administration, has always pushed for affordable and universal healthcare. He has consistently pointed out the shortcomings of the <a href="https://www.benzinga.com/personal-finance/25/04/44674382/mark-cuban-says-big-insurance-companies-and-pbms-control-healthcare-costs-everyone-has-to-kiss-their-a-and-accept-the-complications">U.S. healthcare system</a>, which is further complicated by large insurance companies and pharmacy benefit managers.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/04/44858847/nancy-pelosi-called-us-china-trade-a-job-loserold-remarks-reemerge-amid-trump-tariff-push" target="_blank" rel="noreferrer noopener">Nancy Pelosi Called US-China Trade &#8220;A Job Loser:&#8221; Old Remarks Reemerge Amid Trump Tariff Push</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Mark Cuban Says This Trump Healthcare Order 'Could Save Hundreds Of Billions'

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) stock is trading higher on Thursday after the U.S. healthcare giant reported topline Phase 3 results from ACHIEVE-1 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">diet and exercise alone</a>.
Eli Lilly adds that Orforglipron is the first oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44859676/lillys-oral-glp-1-orforglipron-demonstrated-statistically-significant-efficacy-results-and-a-safet" rel="noreferrer noopener">complete a Phase 3 trial</a>.&nbsp;
The trial randomized 559 participants to receive either 3 mg, 12 mg, or 36 mg orforglipron or placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44824190/eli-lillys-mounjaro-launch-triggers-weight-loss-craze-in-india-novo-nordisk-seeks-to-move-up-wegovy-launch" rel="noreferrer noopener">Eli Lilly&#8217;s Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch</a>
Lilly said on Thursday that it expects to submit orforglipron for weight management to global regulatory agencies by the end of this year, with the submission for the treatment of type 2 diabetes anticipated in 2026.&nbsp;
In the first Phase 3 trial of the ACHIEVE program, orforglipron met the primary endpoint of superior A1C (blood sugar) reduction compared to placebo at 40 weeks, lowering A1C by an average of 1.3% to 1.6% from a baseline of 8.0%, using the efficacy estimand.
In a key secondary endpoint, more than 65% of participants taking the highest dose of orforglipron achieved an A1C less than or equal to 6.5%, below the American Diabetes Association&#8217;s defined threshold for diabetes.
In an additional key secondary endpoint, participants taking orforglipron lost an average of 16.0 lbs (7.9%) at the highest dose.
Given that participants had not yet reached a weight plateau when the study ended, it appears that full weight reduction had not yet been attained.
For the treatment-regimen estimand, each dose of orforglipron led to statistically significant A1C reductions.
In the key secondary endpoint for body weight, 12 mg and 36 mg doses led to statistically significant reductions.
<ul>
<li>A1C reduction: 1.2% (3 mg), 1.5% (12 mg), 1.5% (36 mg), 0.4% (placebo)</li>
<li>Percent weight reduction: 4.5% (3 mg), 5.8% (12 mg), 7.6% (36 mg), 1.7% (placebo)</li>
<li>Weight reduction: 4.2 kg (9.3 lbs; 3 mg), 5.2 kg (11.5 lbs; 12 mg), 7.2 kg (15.8 lbs; 36 mg), 1.5 kg (3.4 lbs; placebo)</li>
</ul>
The overall safety profile of orforglipron in ACHIEVE-1 was consistent with the established&nbsp;GLP-1&nbsp;class. The most commonly reported adverse events were gastrointestinal-related and generally mild to moderate.
The most common adverse events for participants treated with orforglipron (3 mg, 12 mg, and 36 mg, respectively) were diarrhea (19%, 21%, and 26%) vs. 9% with placebo, nausea (13%, 18% and 16%) vs. 2% with placebo, dyspepsia (10%, 20% and 15%) vs. 7% with placebo, constipation (8%, 17% and 14%) vs. 4% with placebo, and vomiting (5%, 7% and 14%) vs. 1% with placebo.
Overall treatment discontinuation rates due to adverse events were 6% (3 mg), 4% (12 mg), and 8% (36 mg) for orforglipron vs. 1% with placebo.
No hepatic safety signal was observed.
Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) oral danuglipron was tied to &#8220;high rates&#8221; of mild gastrointestinal side effects, leading to more than half of the patients across all dose groups&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44790653/pfizer-discontinues-once-daily-weight-loss-pill-over-liver-injury-in-one-patient" rel="noreferrer noopener">dropping out from the trial</a>.&nbsp;
More results from the ACHIEVE Phase 3 clinical trial program will be shared later this year, along with findings from the ATTAIN Phase 3 clinical trial program evaluating orforglipron for weight management.
Price Action: LLY stock is up 11.3% at $817.99 during the premarket session at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/04/44860240/unitedhealth-slashes-2025-outlook-on-medicare-funding-reductions-stock-crashes" target="_blank" rel="noreferrer noopener">UnitedHealth Slashes 2025 Outlook On Medicare Funding Reductions, Stock Crashes</a></li>
</ul>
Photo by Jonathan Weiss via Shutterstock

Eli Lilly's Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars

Government

Regulations

CDC Advisory Committee On Immunization Practices Voted To Expand Pfizer's RSV Vaccine ABRYSVO To Include Adults Aged 50 To 59 At Increased Risk Of Disease

US President Donald Trump issued a multi-part executive order on Tuesday to lower drug prices and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">reduce Medicare costs</a>.
Within 60 days, the Secretary of Health and Human Services is instructed to seek guidance for the Medicare Drug Price Negotiation Program for initial price applicability year 2028 and how drugmakers should implement the set prices in 2026, 2027, and 2028.
<ul>
<li>This guidance will focus on greater transparency, selecting high-cost drugs, and safeguarding pharmaceutical innovation.</li>
<li>Additionally, the administration seeks to eliminate a key disparity in how Medicare treats small-molecule drugs compared to biologics, discouraging investment in more affordable treatments.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a>
The White House is also <a target="_blank" href="https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/" rel="noreferrer noopener">targeting</a> the rising costs seniors face under Medicare. A new payment model will be tested within a year to obtain better value for high-cost drugs and biologicals, including those not subject to price negotiations.
Further, the administration wants to align Medicare payments with actual hospital acquisition costs through a national survey, with potential reimbursement adjustments following the results.
To reform Medicaid drug pricing, the administration will develop recommendations linking drug payments to their value and ensuring accurate rebate payments from manufacturers. The initiative also aims to assist states in managing spending while promoting innovation in Medicaid reimbursement.
Affordability for life-saving medications is another key focus: Community health centers will be required to offer insulin and epinephrine at or below discounted 340B prices to low-income individuals with high out-of-pocket costs or no insurance, with compliance tied to eligibility for future federal grants..
To address price manipulation in the supply chain, the administration calls for reevaluating middlemen roles, such as pharmacy benefit managers, and seeking transparency in their compensation structures. Within 90 days, recommendations to promote a more efficient pharmaceutical market are expected.
Other planned reforms include accelerating FDA approvals for generics and over-the-counter conversions, streamlining the drug importation program, and ensuring Medicare payments do not incentivize hospital-based care over less costly physician offices.
Lastly, federal agencies will investigate anti-competitive practices by drug manufacturers, with public listening sessions and policy recommendations expected within six months.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44826592/netflix-wants-to-be-the-next-1-trillion-company-analyst-highlights-growth-path" target="_blank" rel="noreferrer noopener">Netflix Wants To Be The Next $1 Trillion Company, Analyst Highlights Growth Path</a></li>
</ul>
Photo by Aria Armoko via Shutterstock

ABBV

BIIB

BMRN

GILD

REGN

VRTX

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction

Novavax, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) on Tuesday released preliminary results from the SHIELD-Utah&nbsp;study investigating the effects of systemic and local reactogenicity of COVID-19 <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">vaccine doses in&nbsp;Utah</a>.
SHIELD-Utah&nbsp;was a prospective, interventional study conducted at the&nbsp;University of Utah&nbsp;Health.
The study showed Novavax&#8217;s COVID-19 Vaccine, Adjuvanted (2024-2025 Formula), targeting the JN.1 strain, resulted in fewer and less severe reactogenicity symptoms when compared with the Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)-BioNTech SE&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44808832/shield-utah-study-shows-novavaxs-covid-19-vaccine-induces-lower-reactogenicity-symptoms-compared-t" rel="noreferrer noopener">mRNA 2024-2025 vaccine</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44634464/despite-headwinds-biotech-sell-off-could-offer-buying-opportunity-bofa" rel="noreferrer noopener">Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst</a>
This real-world study, conducted between September and&nbsp;December 2024, also showed that the impact of symptoms on daily activities, including work and family responsibilities, was lower in recipients of Novavax&#8217;s vaccine.
&#8220;The risk of side effects or reactogenicity has been shown to be a major decision factor for those opting to get vaccinated. Our findings of lower frequency and intensity of reactogenicity symptoms from the protein-based COVID-19 vaccine observed in SHIELD-Utah&nbsp;add valuable insights to the public debate weighing choice and value of COVID-19 vaccination,&#8221; said&nbsp;Sarang K. Yoon, DO, MOH, Principal Investigator,&nbsp;University of Utah&nbsp;Health.
As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly fewer reactogenicity events than Pfizer-BioNTech recipients.
On average, Novavax recipients experienced 1.7 symptoms versus 2.8 systemic symptoms in Pfizer-BioNTech recipients.
43.8% of Pfizer-BioNTech recipients experienced at least one symptom of Grade 2 or higher compared to 24.2% of Novavax recipients.
Local reactogenicity events also showed an absolute difference of 12.5% fewer in Novavax recipients versus Pfizer-BioNTech recipients.
The impact of symptoms on daily activities, including work, showed the hours of reduced activity were lower in Novavax recipients versus Pfizer-BioNTech recipients (mean=0.7 vs. 1.4h and mean=0.8 vs. 2.4h for missed work and less productivity, respectively).
Earlier this month, the regulators missed the deadline for deciding to grant full approval to <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44613147/fda-delays-full-approval-decision-on-novavaxs-covid-19-vaccine" rel="noreferrer noopener">Novavax&#8217;s COVID-19 shot</a>.
Price Action: NVAX stock is down 3.60% at $6.18 at the last check Tuesday
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/04/44820082/global-electric-vehicle-sales-jump-in-march-what-country-leads-in-sales" target="_blank" rel="noreferrer noopener">Global Electric Vehicle Sales Jump In March: What Country Leads In Sales?</a></li>
</ul>
Image: Shutterstock

BNTX

NVAX

Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study

When the market throws a delightful little soiree for the bears and headlines scream of doom, gloom and capital destruction, it often feels like it&#8217;s the end of it all.
But odds are the world is not going to end.
It was the same in previous bear markets.
During the 1998 Russian crisis and the collapse of Long Term Capital Management, closed-door meetings at the New York offices of the Federal Reserve were held, in which participants discussed who would pony up enough cash to save the financial system.
Warren Buffett passed. Instead, a bunch of Wall Street and a few French banks stepped up with the necessary cash.
During the Great Financial Crisis, it felt like the financial system&#8217;s implosion was always just seconds away.
In the initial stages of the COVID-19 pandemic, the end of the world was the lead story for weeks on end.
In every case, the world survived and stocks recovered.
In each case, this was the winning investment strategy during the bear market.
If the end does come, I suspect none of us will be concerned about our stock portfolio.
I do not recall Charlton Heston asking Cornelius or Zira about the price of IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) or General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) in Planet of the Apes.
Rick Grimes of The Walking Dead never takes a break from killing zombies to call his broker.
If the world survives the tariff war of 2025, we might want to make some of the moves that paid off in the aftermath of prior almost-end-of-the-world events.
One of the best strategies is buying dividends and dividend growth.
Investors who bought stocks like Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Altria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) and CapitalOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) in early 2009 not only locked in high levels of income, their gains over the next decade were spectacular.
Buying high-yield stocks like Unum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>), Tanger Outlets (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKT#NYSE">SKT</a>) and Marathon Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) in the spring of 2020 has also worked out extraordinarily well for investors who allowed rational thinking to overcome fear.
Unless the world ends, this time should offer the same opportunities to lock in high yields from companies that also offer the potential for outsized long-term gains.
Shares of Pfizer have once again fallen to levels that make the stock a high-yielding opportunity for patient investors.
Pfizer has a diverse drug portfolio and is in a strong position in the vaccine markets. Going forward, they are shedding the off-patent drug business to focus on innovation and newer products.
Pfizer generates massive amounts of free cash flow, which is used to pay down debt, buy back stock and pay dividends.
The company plans to pay out 50% of cash flow as dividends so the payout should continue to grow over time.
Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) is one of the best-positioned auto companies in the current environment and should do very well as the trade war progresses towards a conclusion.
Ford continues to dominate the pickup truck market and I don&#8217;t see that changing anytime soon.
Ford intends to have a presence in the EV market but will not abandon the traditional market anytime soon. The Mustang Mach-E and Lightning F-150 electric vehicles are both selling well and attracting customers who have never considered Ford products before.
Ford has focused on reducing debt and strengthening its balance sheet over the past few years, and this strategy is working.
The company currently has over $25 billion in cash and securities on the books.
The stock is currently yielding over 7% and has excellent long-term appreciation potential from current levels.
UPS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) shares have also fallen to the level where the dividend is attractive. At the current price, the yield is over 7%.
UPS seems like a solid bet, even with some bumps in the road ahead. They&#8217;re the big dog in package delivery, handling way more daily packages than FedEx in the US.
<h2 class="wp-block-heading">Volatile Markets Demand Speed: 60% Off Flash Sale</h2>
When the S&amp;P swings wildly, being first matters. Access breaking news up to 30 minutes before others, customized scanners, and instant alerts—all for 60% off. This flash sale won't survive in volatile markets—<a href="https://www.benzinga.com/pro/register-spring-sale">secure your discount </a>now!
Editorial content from our Expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies which are neither expressly or impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

This Strategy Outperforms In Bear Markets

<a href="https://www.youtube.com/watch?v=Dt_sprpZXqk">https://www.youtube.com/watch?v=Dt_sprpZXqk</a>
&nbsp;

Global

President Trump Says Will Do Tariffs On Imported Pharmaceuticals; All I Have To Do Is Impose A Tariff; Pharmaceutical Tariffs In Not Too Distant Future

Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>),&nbsp;&nbsp;Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) stocks are trading higher on Monday.
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) announced on Monday that it will discontinue the development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist being investigated for <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">chronic weight management</a>.
A single asymptomatic participant in one of the dose-optimization studies experienced potential drug-induced liver injury, which resolved after discontinuation of danuglipron.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42827918/viking-therapeutics-structure-therapeutics-positioned-as-key-pharma-partners-for-weight-loss-products-analyst" rel="noreferrer noopener">Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst</a>
Pfizer is one of several drugmakers working to develop an alternative to injectable weight loss drugs. Still, it&#8217;s far behind rivals like Eli Lilly and Novo Nordisk, who already lead the market with weekly injections.
Eli Lilly is developing orforglipron, which could be the first small-molecule weight-loss pill when it launches in 2026. This would give Eli Lilly a two-year lead <a href="https://www.benzinga.com/general/biotech/24/10/41137681/eli-lilly-nears-first-trillion-pharma-title-but-investors-caution-amid-sky-high-valuation" target="_blank" rel="noreferrer noopener">before rivals catch up</a>.
In March, Viking Therapeutics completed subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of VK2735, the company&#8217;s dual agonist of the GLP-1 and glucose-dependent <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44490486/viking-therapeutics-announces-completion-of-enrollment-in-phase-2-venture-oral-dosing-trial-of-vk2" rel="noreferrer noopener">insulinotropic polypeptide (GIP) receptors</a>.
VK2375 is being developed in oral and subcutaneous formulations for various metabolic disorders, such as obesity. Viking expects to report data from the study in <a href="https://www.benzinga.com/general/biotech/24/11/41712739/viking-therapeutics-reveals-early-stage-from-experimental-oral-obesity-drug-showing-weight-loss-a" target="_blank" rel="noreferrer noopener">the second half of 2025</a>.
Viking plans to initiate Phase 3 development with the subcutaneous formulation of VK2735 in the first half of 2025.
In June 2024, Structure Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) unveiled 12-week topline obesity data from its <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39144875/structure-therapeutics-obesity-candidate-is-very-competitive-to-eli-lillys-orforgli" target="_blank" rel="noreferrer noopener">Phase 2a study of GSBR-1290</a>.
In the Phase 2a obesity study, GSBR-1290 demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/06/g39133591/structure-therapeutics-reports-positive-topline-data-from-its-phase-2a-obesity-study-and-capsule-t" rel="noreferrer noopener">6.2% at 12 weeks</a>.&nbsp;
In July 2024, Roche Holdings AG&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announced topline results from two arms of an ongoing multi-part Phase 1 clinical trial for CT-996 for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39812408/roche-highlights-encouraging-data-from-newly-acquired-second-weight-loss-drug-candidate-in-early-" rel="noreferrer noopener">type 2 diabetes and obesity</a>.
The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinically meaningful placebo-adjusted mean weight loss of -6.1% within four weeks.
This data is better compared <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39817857/obesity-drugs-focused-stocks-tumble-on-wednesday-whats-going-on-with-eli-lilly-novo-nordisk-vikin" rel="noreferrer noopener">to existing competitors</a>.
In June 2023, Pfizer discontinued the clinical development of another GLP-1-RA candidate, lotiglipron (PF-07081532), due to pharmacokinetic data from Phase 1 studies and laboratory measurements of elevated&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/35757948/what-are-pfizers-prospects-in-obesity-pill-market-analysts-say-optimism-cautiousness-surround-wit" rel="noreferrer noopener">transaminases (liver enzymes)</a>.
In March, Altimmune Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) unveiled the first disclosure of Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) as potential developments&nbsp;for its <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44330443/altimmune-expands-weight-loss-drug-pemvidutides-potential-to-alcohol-related-disorders" rel="noreferrer noopener">obesity drug, pemvidutide</a>.
Phase 2 trials for pemvidutide in AUD and ALD are expected to start in the second and third quarters of 2025, respectively.
Price Action: LLY stock is up 1.14% at $739.26, NVO stock is up 1.68% at $65.82, ALT stock is up 3.40% at $4.56, VKTX stock is up 13.5% at $25.21
GPCR stock is up 8.36% at $17.23 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44788755/bp-discovers-oil-at-far-south-prospect-in-deepwater-gulf-boosts-upstream-growth-outlook" target="_blank" rel="noreferrer noopener">BP Discovers Oil At Far South Prospect in Deepwater Gulf, Boosts Upstream Growth Outlook</a></li>
</ul>

GPCR

RHHBY

VKTX

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) is discontinuing development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist being investigated for <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">chronic weight management</a>.
Pfizer&#8217;s dose-optimization studies of once-daily formulations of danuglipron (PF-06882961) met key pharmacokinetic objectives. The study confirmed a formulation and dose that could deliver a competitive efficacy and tolerability profile in Phase 3 testing based on earlier studies of <a href="https://www.benzinga.com/pressreleases/25/04/b44784896/pfizer-provides-update-on-oral-glp-1-receptor-agonist-danuglipron" target="_blank" rel="noreferrer noopener">twice-daily danuglipron</a>.
The stopped trials include:
<ul>
<li>Phase 1, open-label <a href="https://clinicaltrials.gov/study/NCT06568731?term=PF-06882961&amp;limit=10&amp;page=2&amp;rank=16" target="_blank" rel="noreferrer noopener">study</a> to evaluate the multiple-dose pharmacokinetics of danuglipron following oral administration in otherwise healthy adult participants with overweight or obesity.</li>
<li>A two-part phase 1, open-label, fixed-sequence <a href="https://clinicaltrials.gov/study/NCT06567327?term=PF-06882961&amp;limit=10&amp;page=2&amp;rank=18" target="_blank" rel="noreferrer noopener">study</a> to evaluate the multiple-dose pharmacokinetics of danuglipron following oral administration and the effects of steady-state danuglipron on the pharmacokinetics of single oral dose of atorvastatin and rosuvastatin in otherwise healthy adult participants with overweight or obesity.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44777882/benzinga-bulls-and-bears-apple-nike-us-steel-and-the-markets-ride-out-ongoing-volatility" rel="noreferrer noopener">Benzinga Bulls And Bears: Apple, Nike, US Steel — And The Markets Ride Out Ongoing Volatility</a>
The company said that while the overall frequency of liver enzyme elevations across the over 1,400 participant safety database of danuglipron is in line with approved agents in the class, a single asymptomatic participant in one of the dose-optimization studies experienced potential drug-induced liver injury, which resolved after discontinuation of danuglipron.
After reviewing the totality of information, including all clinical data generated to date for danuglipron and recent input from regulators, Pfizer has decided to discontinue development of the molecule.
Data from the danuglipron clinical development program will be presented at a scientific forum or submitted for publication in a peer-reviewed journal in the future.
In December 2023, Pfizer reported topline data from the <a href="https://www.benzinga.com/general/biotech/23/12/36041804/this-twice-daily-weight-loss-drug-has-adverse-side-effects-and-pfizer-wants-to-discontinue-it" target="_blank" rel="noreferrer noopener">Phase 2b trial of danuglipron</a>.
The company said the study met its primary endpoint, demonstrating a statistically significant change in body weight from baseline, but danuglipron was tied to "high rates" of mild gastrointestinal side effects, leading to more than half of the patients across all dose groups&nbsp;dropping out from the trial.&nbsp;
Then, Pfizer said the future development of danuglipron will be focused on a once-daily formulation and that it will stop evaluating&nbsp;a twice-daily formulation.
In July 2024, Pfizer selected its preferred once-daily modified-release <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39730398/pfizer-advances-once-daily-weight-loss-pill-as-it-catches-up-to-tap-the-lucrative-market" rel="noreferrer noopener">formulation for danuglipron</a>.
Goldman Sachs noted that it is unlikely to obtain significant tolerability data that could address the main criticisms of the company's Phase 2b <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39753273/with-oral-anti-obesity-candidate-development-pfizer-seeks-relevant-and-competitive-" rel="noreferrer noopener">BID (twice daily) study</a>.
The analyst said, "Further to debates that investors have been contemplating relating to "pill burden" — PFE expects that the study would involve and ultimately advance a single pill QD dose format — which, assuming positive results overall, would be the objective in terms of presentation to advance into a Phase 3 registrational study."
"This underpins the company's decision for further development and commitment to their goal of seeking a relevant and competitive presence in the oral obesity therapeutics market."
Price Action: Pfizer is up 0.71% at $22.06 during the session at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44775384/fda-approves-argenxs-vyvgart-hytrulo-prefilled-syringe-for-self-injection-for-at-home-use-setting" target="_blank" rel="noreferrer noopener">FDA Approves Argenx&#8217;s Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting</a></li>
</ul>
Image: Shutterstock

Pfizer Discontinues Once-Daily Weight Loss Pill Over Liver Injury In One Patient

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pfizer.com%2F&amp;esheet=54237507&amp;newsitemid=20250413297943&amp;lan=en-US&amp;anchor=Pfizer+Inc.&amp;index=1&amp;md5=a3aabb03d15f888d5d0e017aac18c91f">Pfizer Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management.
Pfizer's dose-optimization studies of once-daily formulations of danuglipron (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06567327%3Fterm%3DPF-06882961%26limit%3D10%26page%3D2%26rank%3D18&amp;esheet=54237507&amp;newsitemid=20250413297943&amp;lan=en-US&amp;anchor=NCT06567327&amp;index=2&amp;md5=c65dca627777c49eff20bbbcbeb524a0">NCT06567327</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06568731%3Fterm%3DPF-06882961%26limit%3D10%26page%3D2%26rank%3D16&amp;esheet=54237507&amp;newsitemid=20250413297943&amp;lan=en-US&amp;anchor=NCT06568731&amp;index=3&amp;md5=cb512c8bcc9b4b367d9fcef5079833b5">NCT06568731</a>) met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver a competitive efficacy and tolerability profile in Phase 3 testing, based on earlier studies of twice-daily danuglipron. While the overall frequency of liver enzyme elevations across the over 1,400 participant safety database of danuglipron is in-line with approved agents in the class, a single asymptomatic participant in one of the dose-optimization studies experienced potential drug-induced liver injury which resolved after discontinuation of danuglipron. After a review of the totality of information, including all clinical data generated to date for danuglipron and recent input from regulators, Pfizer has decided to discontinue development of the molecule.
"Cardiovascular and metabolic diseases including obesity remain important areas of unmet medical need, and we plan to continue applying our global capabilities to advance a pipeline of investigational treatments that have the potential to fill critical gaps in patient care, including continued development of our oral GIPR antagonist candidate and other earlier obesity programs," said Chris Boshoff, MD, PhD, Chief Scientific Officer and President, Research and Development at Pfizer. "While we are disappointed to discontinue the development of danuglipron, we remain committed to evaluating and advancing promising programs in an effort to bring innovative new medicines to patients."
Data from the danuglipron clinical development program will be presented at a scientific forum or submitted for publication in a peer-reviewed journal in the future.

Pfizer Discontinues Danuglipron Trials for Chronic Weight Management, Focuses on Other Obesity Treatments

Pfizer's dose-optimization studies of once-daily formulations of danuglipron (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06567327%3Fterm%3DPF-06882961%26limit%3D10%26page%3D2%26rank%3D18&amp;esheet=54237507&amp;newsitemid=20250413297943&amp;lan=en-US&amp;anchor=NCT06567327&amp;index=2&amp;md5=c65dca627777c49eff20bbbcbeb524a0">NCT06567327</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06568731%3Fterm%3DPF-06882961%26limit%3D10%26page%3D2%26rank%3D16&amp;esheet=54237507&amp;newsitemid=20250413297943&amp;lan=en-US&amp;anchor=NCT06568731&amp;index=3&amp;md5=cb512c8bcc9b4b367d9fcef5079833b5">NCT06568731</a>) met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver a competitive efficacy and tolerability profile in Phase 3 testing, based on earlier studies of twice-daily danuglipron. While the overall frequency of liver enzyme elevations across the over 1,400 participant safety database of danuglipron is in-line with approved agents in the class, a single asymptomatic participant in one of the dose-optimization studies experienced potential drug-induced liver injury which resolved after discontinuation of danuglipron. After a review of the totality of information, including all clinical data generated to date for danuglipron and recent input from regulators, Pfizer has decided to discontinue development of the molecule.

Pfizer Announced The Decision To Discontinue The Development Of Danuglipron (PF-06882961), An Oral Glucagon-like Peptide-1 Receptor Agonist Being Investigated For Chronic Weight Management

Benzinga examined the prospects for<a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noreferrer noopener"> many investors' favorite stocks</a> over the last week — here's a look at some of our top stories.
President Donald Trump's hold on global tariffs but imposition of a 145% levy on Chinese imports led to significant market volatility and eroding confidence in the dollar and Treasuries this week. The 30-year Treasury yield briefly reached 5%, indicating the return of bond vigilantes — investors selling bonds in reaction to policy decisions.
Despite the turmoil, certain stocks have outperformed. For instance, Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) have shown resilience amid the market's fluctuations, demonstrating robust fundamentals and strategic positioning that appeal to investors even during uncertain times.
Overall, while the broader market faces challenges from escalating trade tensions and policy uncertainties, select companies continue to thrive, highlighting the importance of strategic agility and strong fundamentals in navigating volatile economic landscapes.
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look.
The Bulls
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44696168/apple-is-a-buying-opportunity-again-as-key-valuation-level-flashes-green-bank-of-america-says">"Apple Is A ‘Buying Opportunity' Again As Key Valuation Level Flashes Green, Bank Of America Says"</a>, by Piero Cingari, reports that Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares have dropped 17% since April 2, more than double the S&amp;P 500's decline in the same period, and Bank of America analyst Wamsi Mohan views this as a buying opportunity, citing historical data showing average gains of 17% one year after Apple's P/E ratio compresses under 25x.
<a href="https://www.benzinga.com/news/buybacks/25/04/44674899/broadcom-stock-jumps-on-10-billion-buyback-authorization">"Broadcom Stock Jumps On $10 Billion Buyback Authorization"</a>, by Adam Eckert, reports that Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) shares rose after the company authorized a $10 billion share repurchase program through the end of 2025, reflecting confidence in its semiconductor and infrastructure software businesses.
<a href="https://www.benzinga.com/25/04/44683383/marvell-plays-ai-hardball-divestiture-sparks-155-upside-says-analyst">"Marvell Plays AI Hardball: Divestiture Sparks 155% Upside, Says Analyst"</a>, by Surbhi Jain, reports that Marvell Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) sold its automotive Ethernet business to Infineon Technologies AG for $2.5 billion, prompting JPMorgan analyst Harlan Sur to reaffirm an Overweight rating and set a $130 price target — implying a 155% upside — as the company intensifies its focus on AI and cloud data center growth.
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/news/earnings/25/04/44701164/aehr-test-systems-stock-climbs-after-q3-results-details">Aehr Test Systems Stock Climbs After Q3 Results: Details</a>
<a href="https://www.benzinga.com/government/regulations/25/04/44752313/health-care-technology-stocks-surge-after-fda-announces-plans-to-phase-out-animal-testing-requirements">Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements</a>
<a href="https://www.benzinga.com/news/large-cap/25/04/44725578/technology-stocks-outperform-after-trumps-tariff-pause-microchip-technology-amd-lead-sector-higher">Technology Stocks Outperform After Trump's Tariff Pause: Microchip Technology, AMD Lead Sector Higher</a>
The Bears
<a href="https://www.benzinga.com/news/global/25/04/44741043/nike-stock-tumbles-as-us-china-trade-war-intensifies-what-you-need-to-know">"Nike Stock Tumbles As US-China Trade War Intensifies: What You Need To Know"</a>, by Adam Eckert, reports that Nike Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) shares fell 10.3% to $53.18 amid escalating U.S.-China trade tensions, as the company's reliance on imports from China, Vietnam, and Indonesia exposes it to new tariffs, including a 145% rate on Chinese goods.
<a href="https://www.benzinga.com/news/global/25/04/44725016/us-steel-stock-tumbles-as-trump-says-we-dont-want-to-see-it-go-to-japan">"US Steel Stock Tumbles As Trump Says ‘We Don't Want To See It Go To Japan'"</a>, by Adam Eckert, reports that United States Steel Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) shares fell over 11% in after-hours trading after Trump expressed opposition to the company's acquisition by Nippon Steel, stating, "We don't want to see it go to Japan."
<a href="https://www.benzinga.com/25/04/44684590/microns-meltdown-tariff-surcharge-adds-salt-to-the-stocks-slide">"Micron's Meltdown: Tariff Surcharge Adds Salt To The Stock's Slide"</a>, by Surbhi Jain, reports that Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) shares plunged over 22% in five trading days as the company imposed a tariff-related surcharge on U.S. customers, exacerbating bearish technical signals with the stock trading below key moving averages and nearing oversold RSI levels.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/trading-ideas/technicals/25/04/44695368/death-cross-alert-alphabet-stock-drops-the-signal-bears-pick-it-up">Death Cross Alert: Alphabet Stock Drops The Signal, Bears Pick It Up</a>
<a href="https://www.benzinga.com/25/04/44715119/pfizer-stock-is-sliding-wednesday-whats-going-on">Pfizer Stock Is Sliding Wednesday: What's Going On?</a>
<a href="https://www.benzinga.com/25/04/44748974/death-cross-meets-tax-threat-tsms-chip-dip-has-more-than-just-technicals-to-blame">TSMC Triggers Death Cross As Trump Tariff Threats Add To Investor Concerns</a>
Keep up with all the latest breaking news and trading ideas by following <a href="https://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener">Benzinga</a><a href="http://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener"> on X</a>.
Image created using artificial intelligence via Midjourney.

AAPL

AEHR

AMZN

AVGO

GOOGL

MCHP

MRVL

TSLA

Benzinga Bulls And Bears: Apple, Nike, US Steel — And The Markets Ride Out Ongoing Volatility

Even as President Donald Trump paused the reciprocal tariffs for 90 days on Wednesday, he later confirmed in a conversation with reporters at his Oval Office that pharmaceutical companies would face tariffs.
What Happened: The rally in pharma stocks was short-lived after the stocks reversed course on Thursday. When a reporter asked President Trump if he would go ahead and levy tariff duties on pharmaceutical stocks, he said, &#8220;Yeah, well, I will be because we want them coming back.&#8221;
&#8220;You know, we realized during COVID-19 that we don&#8217;t make our drugs and our pharmaceuticals in this country. So, I realized that, and it was a big realization,&#8221; he added.
Citing the emergency during COVID-19, he stated that he wanted the pharma companies to produce drugs in the U.S.
&#8220;We had to go to China to get drugs, we had to go to other places, we don&#8217;t make it. That&#8217;s because we let them leave, and now if they want to come back, we&#8217;re going to put tariffs on the pharmaceutical companies, and they&#8217;re going to all want to come back,&#8221; Trump said.
The pharma stocks tumbled on Thursday after Trump&#8217;s confirmation of tariffs.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Pharma Stocks</td>
<td>Thursday&#8217;s Performance</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>-4.35%</td>
<td>-7.35%</td>
<td>-5.09%</td>
</tr>
<tr>
<td>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</td>
<td>-3.14%</td>
<td>-2.92%</td>
<td>3.99%</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>-6.10%</td>
<td>-11.15%</td>
<td>2.73%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>-5.26%</td>
<td>-23.60%</td>
<td>-40.63%</td>
</tr>
<tr>
<td>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>-3.87%</td>
<td>-18.87%</td>
<td>-18.03%</td>
</tr>
<tr>
<td>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</td>
<td>-3.66%</td>
<td>10.36%</td>
<td>47.71%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>-5.32%</td>
<td>-21.80%</td>
<td>-38.53%</td>
</tr>
<tr>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>-3.33%</td>
<td>8.54%</td>
<td>4.23%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>-1.51%</td>
<td>3.24%</td>
<td>-0.07%</td>
</tr>
</tbody>
</table>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/04/44755181/pentagon-slashes-5-1-billion-in-accenture-deloitte-booz-allen-contracts-thats-a-lot-of-consulting">Pentagon Slashes $5.1 Billion In Accenture, Deloitte, Booz Allen Contracts: &#8216;That&#8217;s A Lot Of Consulting&#8217;</a>
Why It Matters: Despite a 90-day pause on reciprocal tariffs, base global tariffs of 10% and China tariffs of 125%, along with sector-specific tariffs of 25% on steel and aluminum, auto, and auto parts remain in place. Adding to it, the President hinted that he could soon announce tariffs on pharmaceutical companies.
Here are some of the pharmaceutical industry-linked exchange-traded funds that could be impacted.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>-7.02%</td>
<td>-7.51%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-7.04%</td>
<td>-6.08%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-10.13%</td>
<td>-4.37%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-14.05%</td>
<td>-11.45%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>2.88%</td>
<td>0.35%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-11.54%</td>
<td>-10.18%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-41.35%</td>
<td>-43.86%</td>
</tr>
</tbody>
</table>
</figure>
Price Action: After Thursday&#8217;s fall, following Wednesday&#8217;s rebound, the Nasdaq 100 index was 17.46% lower than its previous high of 22,222.61 points. The S&amp;P 500 index was down 14.31% from its record of 6,147.43 points, and the Dow Jones declined 12.16% from its 52-week high of 45,073.63 points.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, ended lower on Thursday. The SPY was down 4.38% to $524.58, while the QQQ declined 4.25% to $446.18, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44728276/spy-qqq-call-volumes-spiked-minutes-before-tariff-pause-announcement-alexandria-ocasio-cortez-demands-disclosure-from-congress-members" target="_blank" rel="noreferrer noopener">SPY, QQQ Call Volumes Spiked Minutes Before Tariff Pause Announcement: Alexandria Ocasio-Cortez Demands Disclosure From Congress Members</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

AMGN

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies

U.S.&nbsp;President Donald Trump, on Tuesday, disclosed plans for a "major tariff" on <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">foreign pharmaceuticals</a>.
"We're&nbsp;going to be announcing very&nbsp;shortly a major tariff on&nbsp;pharmaceuticals… when they hear that&nbsp;they will leave China, they&nbsp;will leave other places because… most of their product&nbsp;is sold here," Trump expressed at&nbsp;a National Republican <a target="_blank" href="https://www.benzinga.com/25/04/44708204/trump-hints-at-major-tariff-on-imported-pharmaceuticals-us-pharma-stocks-tumble-in-wednesday-pre-market" rel="noreferrer noopener">Congressional Committee&nbsp;dinner</a>.
He also told reporters on board his Air Force One plane that "pharma" tariffs would arrive "at a level that you haven't really seen before," saying these would be announced "in the near future," BBC <a target="_blank" href="https://www.bbc.com/news/articles/cedyylj1v32o" rel="noreferrer noopener">report</a> added.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44698325/trump-tariff-strategy-self-inflicted-market-debacle-says-wedbush-analyst" rel="noreferrer noopener">Trump Tariff Strategy Creates ‘Self-Inflicted Market Debacle': Analyst</a>
When President Trump announced tariffs last week, he excluded pharmaceuticals from the new tariffs, likely a relief for the industry under pressure following his prior comments suggesting a 25% tariff&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44652075/us-tariffs-spare-drugmakers-but-threaten-diabetes-device-industry" rel="noreferrer noopener">on pharmaceutical imports</a>.&nbsp;
On Wednesday, in a surprise announcement from President Donald Trump, a 90-day pause on tariffs for countries that have not retaliated <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">against U.S. trade measures.</a>
The news ignited a broad risk-on rally, catapulting major indices to multi-month highs and sending volatility plunging.
Trump's latest Truth Social post slammed China for showing "a lack of respect" and declared an immediate 125% tariff hike on Chinese goods.
"At some point, hopefully in the near future, China will realize that the days of ripping off the U.S.A. and other Countries is no longer sustainable or acceptable," he said.
He praised the over 75 countries that, in his words, "have not, at my strong suggestion, retaliated in any way, shape, or form."
As a reward, those countries would benefit from a temporary 10% reciprocal tariff and a 90-day pause on additional duties.
The biopharma industry has historically been shielded from tariffs, including during Trump's first term.
Although Trump didn't provide many details, his remarks have unsettled buyers, especially those who depend on medicines from India. India provides nearly half of all generic drugs used in the U.S., helping cut billions from healthcare costs.
The U.S. is a major market, buying about a third of India's $13 billion in yearly drug exports.
Indian drug companies warn that if tariffs are added, they'd have to raise prices—which could increase healthcare costs in the U.S.
Even though some companies like Cipla and Dr. Reddy's Laboratories Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) have factories in the U.S., most say it's too expensive to move production for low-profit generic drugs.
BofA Securities analyst says if the Trump administration plans to impose tariffs on the pharmaceutical industry, it would likely do so through a "Section 232 investigation" under the Trade Expansion Act of 1962 to determine whether importing certain goods threatens national security.
The typical timeline for a Section 232 investigation is about a year. If the same timeline applied here, tariffs on drug imports likely wouldn't take effect until late in the year—at the earliest.
It's unclear whether the Section 232 investigation into the drug industry is about to start, but based on recent comments from the administration, it seems possible. However, launching an investigation doesn't guarantee that tariffs will follow.
As the first quarter 2025 earnings season starts soon, analyst Tim Anderson says it will be worth watching whether companies discuss potential tariffs during earnings calls.
That said, any actual earnings impact likely wouldn't show up until sometime after 2025, which could leave investors with more questions than answers.
Wedbush analyst Daniel Ives <a target="_blank" href="https://www.benzinga.com/25/04/44698325/trump-tariff-strategy-self-inflicted-market-debacle-says-wedbush-analyst" rel="noreferrer noopener">on Tuesday wrote</a> that "saying we can just make this in the USA" understates how complex the supply chain in Asia really is—and how electronics, chips, semiconductors, hardware, and smartphones have been built for U.S. consumers over the past 30 years."
Shares of major drugmakers such as Gilead Sciences&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Eli Lilly&nbsp;And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), AstraZeneca&nbsp;Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Roche&nbsp;Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>), Sanofi&nbsp;SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), Novartis&nbsp;AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), Argenx&nbsp;SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>), UCB&nbsp;SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJY#OTC">UCBJY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJF#OTC">UCBJF</a>), Novo Nordisk&nbsp;A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) fell on Wednesday, only reverse course later after the 90-day tariff pause.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44723376/goldman-sachs-scraps-recession-call-after-trumps-surprise-tariff-pause-as-wall-street-marks-strongest-day-since-2008" target="_blank" rel="noreferrer noopener">Goldman Sachs Scraps Recession Call After Trump's Surprise Tariff Pause As Wall Street Marks Strongest Day Since 2008</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

ARGX

UCBJF

UCBJY

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline

Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) shares are moving lower Wednesday alongside several pharmaceutical giants after President Donald Trump indicated that tariffs on pharmaceutical companies <a href="https://www.benzinga.com/25/04/44708204/trump-hints-at-major-tariff-on-imported-pharmaceuticals-us-pharma-stocks-tumble-in-wednesday-pre-market">are on the horizon</a>.
What Happened: At a dinner on Capitol Hill with House Republicans Tuesday night, Trump announced that &#8220;major&#8221; tariffs on pharmaceutical products made outside the U.S. are coming &#8220;very shortly,&#8221; according to the <a href="https://www.wsj.com/livecoverage/stock-market-trump-tariffs-trade-war-04-09-25/card/trump-defends-tariffs-announces-pharmaceutical-levies-coming-soon-dorFjXxnYvU8Xm0iRrGb">Wall Street Journal</a>.
&#8220;We're going to tariff our pharmaceuticals and once we do that they're going to come rushing back into our country because we're the big market,&#8221; Trump reportedly said. 
&#8220;So we're going to be announcing very shortly a major tariff on pharmaceuticals and when they hear that, they will leave China, they will leave other places because they have to — most of their product is sold here.&#8221;
Check This Out: <a href="https://www.benzinga.com/25/04/44708618/china-retaliates-with-massive-84-tariff-hike-on-us-goods-amid-escalating-trade-war">Xi Jinping Hits Back: China Raises Tariffs On US Goods To 84%, Doubling Down On Trade War</a>
The report indicates that Trump claimed the U.S. is currently generating approximately $2 billion from tariffs per day. He also reportedly said countries are &#8220;dying to make a deal&#8221; following his sweeping reciprocal tariff announcement.
Trump&#8217;s tariffs went into effect on Wednesday, including a massive 104% tariff on goods from China. China responded by hiking tariffs on U.S. imports from 34% to 84%, deepening the trade war between the world&#8217;s two largest economies.
&#8220;There are no winners in a trade war,&#8221; China&#8217;s commerce ministry reportedly said in a statement. &#8220;China does not want one, but the government will never allow the legitimate rights and interests of the Chinese people to be harmed or taken away.&#8221;
Pfizer is one of the world&#8217;s largest pharmaceutical companies, with annual sales above $63 billion in 2024. Shares are down approximately 20% year-to-date. 
UBS analyst Trung Huynh maintained Pfizer with a <a href="https://www.benzinga.com/analyst-stock-ratings">Neutral rating</a> and lowered the price target from&nbsp;$28&nbsp;to&nbsp;$24 on Tuesday. Goldman Sachs downgraded Pfizer to Neutral and lowered its price target from $32 to $25. 
PFE Price Action: <a href="http://benzinga.com/quote/pfe">Pfizer shares</a> were down 2.77% at $21.24 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: <a href="https://www.shutterstock.com/g/ShU_studio">ShU studio</a>/Shutterstock.

Pfizer Stock Is Sliding Wednesday: What's Going On?

President Donald Trump has declared that his administration is on the brink of imposing a significant tariff on <a href="https://in.benzinga.com/markets/25/04/44627820/trumps-reciprocal-tariffs-on-india-exempt-pharma-easing-mark-cubans-price-hike-concerns">pharmaceuticals imported from foreign countries.</a>
What Happened: President Trump, on Tuesday, disclosed plans for a &#8220;major tariff&#8221; on foreign pharmaceuticals. Trump is hopeful that this move will prompt drug companies to shift their operations to the U.S., <a href="https://www.theguardian.com/australia-news/2025/apr/09/donald-trump-flags-major-tariff-on-pharmaceuticals-as-us-senator-criticises-whack-on-australia">reported</a> The Guardian.
&#8220;We&#8217;re going to be announcing very shortly a major tariff on pharmaceuticals&#8230; when they hear that they will leave China, they will leave other places because&#8230; most of their product is sold here,&#8221; Trump expressed at a National Republican Congressional Committee dinner.
Despite exempting pharmaceuticals from the recent round of reciprocal tariffs, Trump has been hinting for a long time that the drug industry would be a target. The President is of the view that the tariff will drive drug companies to return to the U.S., considering it is a significant market for their products. &#8220;The advantage we have over everybody is that we&#8217;re the big market. So we&#8217;re going to be announcing very shortly a major tariff on pharmaceuticals,&#8221; Trump added.
The President, however, did not divulge any specifics regarding the tariff increase or its potential impact.
Pharmaceutical stocks across the globe, including GlaxoSmithKline, Sanofi and India&#8217;s Teva Pharmaceuticals, tumbled on Wednesday.
In the U.S. pharmaceutical stocks, Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) declined 3.5%, while Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) lost 3.2%. AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) fell 1.35%, while Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) and Merck &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) dropped 2.94% and 2.75%, respectively, during the Wednesday pre-market trading session.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/25/04/44706492/trump-predicts-tremendous-thundering-landslide-in-2026-midterms-says-tariffs-will-help-republicans-win-bi" target="_blank" rel="noreferrer noopener">Trump Predicts &#8216;Tremendous, Thundering Landslide&#8217; In 2026 Midterms, Says Tariffs Will Help Republicans Win Big</a>
Why It Matters: The $1.7 trillion revenue prescription drug industry has demonstrated a strong resilience to tariffs. The U.S., being the largest and most profitable market globally for prescription drugs and generic products, imports most of these from overseas. In 2024, drug imports reached $213 billion, more than two and a half times the total 10 years earlier. The proposed tariff could, in theory, help bring business back onshore.
However, companies like&nbsp;AstraZeneca Plc and&nbsp;Pfizer&nbsp;have extensive global manufacturing networks, including Ireland, Germany, Canada, the UK, and the U.S and are not restricted to India and China. Sources told Reuters that it could take up to 10 years to build and equip a factory in the U.S., due to stringent regulatory requirements from the U.S. Food and Drug Administration (FDA). Therefore, Trump&#8217;s tariff might necessitate drugmakers to overhaul a complex, expensive manufacturing system.
Meanwhile, after Trump indicated major tariffs on pharmaceuticals, EU drugmakers have urged European Commission President Ursula von der Leyen to take "rapid and radical action" to address the growing "risk of an exodus" to the U.S., following a meeting in Brussels.
<ul>
<li>READ MORE: <a href="https://benzinga.com/25/04/44705972/ford-motor-general-motors-to-witness-higher-demand-as-american-automotives-reap-the-fruit-of-protectionism-says-e" target="_blank" rel="noreferrer noopener">Ford, GM To Witness &#8216;Higher Demand&#8217; As American Carmakers Set To &#8216;Reap The Fruit Of Protectionism,&#8217; Says Expert: Here&#8217;s A List Of Potential Gainers And Losers From Trump Tariffs</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump Hints At 'Major Tariff' On Imported Pharmaceuticals: Pfizer, Eli Lilly, Amgen And Other Stocks Tumble In Wednesday Pre-Market

UBS analyst Trung Huynh maintains Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) with a Neutral and lowers the price target from $28 to $24.

Price Target

UBS Maintains Neutral on Pfizer, Lowers Price Target to $24

Goldman Sachs analyst Asad Haider downgrades Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) from Buy to Neutral and lowers the price target from $32 to $25.

Downgrades

Goldman Sachs Downgrades Pfizer to Neutral, Lowers Price Target to $25

Press Releases

ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1

ViiV Healthcare's investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV

ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP

Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts

Dexcom Appoints Jon Coleman as Chief Commercial Officer

ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program

European Commission Approves Pfizer's RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease

Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24

Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron

ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease

DXCM

MASI

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Comments

Pfizer

Actualités

Dernières nouvelles pour Pfizer (NYSE:PFE) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL